Royalty Pharma (RPRX) Non Operating Income (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Non Operating Income data on file, last reported at -$94.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 4.98% year-over-year to -$94.8 million; the trailing twelve-month figure through Mar 2026 stood at -$229.4 million (down 75.24% YoY), and the FY2025 full-year result was -$235.3 million, down 713.32% from the prior year.
• Non Operating Income fell to -$94.8 million in Q1 2026, from -$32.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $113.8 million in Q2 2022 to a low of -$127.4 million in Q4 2022.
• A 5-year average of -$9.4 million and a median of -$27.2 million in 2024 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income jumped 342.75% in 2024 and slumped 243.52% in 2025, its largest moves.
• Tracing RPRX's Non Operating Income over 5 years: stood at -$127.4 million in 2022, then jumped by 182.19% to $104.7 million in 2023, then tumbled by 125.95% to -$27.2 million in 2024, then declined by 19.53% to -$32.5 million in 2025, then slumped by 191.92% to -$94.8 million in 2026.
• Business Quant data shows RPRX's Non Operating Income at -$94.8 million in Q1 2026, -$32.5 million in Q4 2025, and $17.1 million in Q3 2025.